French immuno-oncology diagnostic company HalioDx has introduced its diagnostic assay, Immunoscore Colon, to guide therapeutic decisions in colon cancer in Europe.
The Immunoscore Colon CE-IVD test allows the identification of patients at high-risk of relapse who can benefit from more intensive adjuvant treatment.
Go deeper with GlobalData
The Immunoscore Colon CE-IVD test analyses the immune contexture of a patient’s colon tumour by quantifying CD3+ and CD8+ T-cells expressed in the tumour and in its invasive margin.
It can predict likelihood of spreading of the cancer cells causing recurrence of the disease after surgery.
HalioDx CEO Vincent FERT said: “The commercial availability of Immunoscore for guiding treatment options in colon cancer is indeed an important critical milestone for HalioDx.
“It is also a landmark event in the era of immuno-oncology, for patients, caregivers and industry as Immunoscore is the first test enabling a robust and precise assessment of the patient’s immune response to cancer.
“We envision that Immunoscore is going to be a standard in cancer diagnostic and will expand its utility to many other cancers”.
A worldwide consortium multicentric study of Immunoscore Colon established its improved prognostic accuracy independently of clinical variables for all patients with Colon Cancer stages I-III along with demonstrating better predictive value with respect to patients’ disease-specific recurrence and survival.
Last year, HalioDx initiated retro-prospective clinical studies of Immunoscore Colon which will analyse several samples derived from patients from randomised clinical trials.
Results of the trials are expected to be released in 2017 and 2018.
